259 related articles for article (PubMed ID: 27211270)
1. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.
Majithia N; Rajkumar SV; Lacy MQ; Buadi FK; Dispenzieri A; Gertz MA; Hayman SR; Dingli D; Kapoor P; Hwa L; Lust JA; Russell SJ; Go RS; Kyle RA; Kumar SK
Leukemia; 2016 Nov; 30(11):2208-2213. PubMed ID: 27211270
[TBL] [Abstract][Full Text] [Related]
2. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
3. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
4. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Royle KL; O'Connor S; Cairns DA; Ashcroft AJ; Williams CD; Hockaday A; Cavenagh JD; Snowden JA; Ademokun D; Tholouli E; Andrews VE; Jenner M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Drayson MT; Brown JM; Morris TCM;
Br J Haematol; 2019 May; 185(3):450-467. PubMed ID: 30729512
[TBL] [Abstract][Full Text] [Related]
5. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
6. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
7. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
8. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
9. Impact of early relapse after auto-SCT for multiple myeloma.
Kumar S; Mahmood ST; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Litzow MR; Gertz MA
Bone Marrow Transplant; 2008 Sep; 42(6):413-20. PubMed ID: 18587435
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.
Lemieux E; Hulin C; Caillot D; Tardy S; Dorvaux V; Michel J; Gastinne T; Rossi C; Legouge C; Touzeau C; Planche L; Loirat M; Lafon I; Moreau P
Biol Blood Marrow Transplant; 2013 Mar; 19(3):445-9. PubMed ID: 23186983
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
13. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.
Chan H; Phillips M; Maganti M; Farooki S; Piza Rodriguez G; Masih-Khan E; Chen C; Prica A; Reece D; Tiedemann R; Trudel S; Kukreti V
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):225-234. PubMed ID: 29397346
[TBL] [Abstract][Full Text] [Related]
14. [Retrospective analysis on therapeutic effect of autologous hematopoietic stem cell transplantation in multiple myeloma patients].
Wang J; Fu CC; Wu DP; Sun AN; Xue SL; Xin X; Hu XH; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Han Y; Ma X; He GS; Chang WR; Chen SN
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):114-8. PubMed ID: 23648347
[TBL] [Abstract][Full Text] [Related]
15. Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma.
Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Gavriatopoulou M; Migkou M; Gika D; Fotiou D; Kanellias N; Ziogas DC; Ntanasis-Stathopoulos I; Mparmparousi D; Gatou A; Katopi D; Manios E; Liontos M; Giannouli S; Tsirigotis P; Terpos E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):445-452. PubMed ID: 32284296
[TBL] [Abstract][Full Text] [Related]
16. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.
Kumar SK; Dispenzieri A; Fraser R; Mingwei F; Akpek G; Cornell R; Kharfan-Dabaja M; Freytes C; Hashmi S; Hildebrandt G; Holmberg L; Kyle R; Lazarus H; Lee C; Mikhael J; Nishihori T; Tay J; Usmani S; Vesole D; Vij R; Wirk B; Krishnan A; Gasparetto C; Mark T; Nieto Y; Hari P; D'Souza A
Leukemia; 2018 Apr; 32(4):986-995. PubMed ID: 29263438
[TBL] [Abstract][Full Text] [Related]
17. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
18. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
[TBL] [Abstract][Full Text] [Related]
20. Relapsed multiple myeloma: who benefits from salvage autografts?
Chow AW; Lee CH; Hiwase DK; To LB; Horvath N
Intern Med J; 2013 Feb; 43(2):156-61. PubMed ID: 22757772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
